...
首页> 外文期刊>Medicine. >Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus
【24h】

Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus

机译:用门静脉肿瘤血栓肝切除肝切除或常规化学栓塞

获取原文
获取原文并翻译 | 示例
           

摘要

The role of hepatic resection in hepatocellular carcinoma (HCC) with accompanying portal vein tumor thrombus (PVTT) remains controversial. This study aimed to evaluate the surgical outcomes of hepatic resection compared with those of transarterial chemoembolization (TACE) in HCC patients. A retrospective study was conducted using the medical records of 230 HCC patients with portal vein invasion who underwent hepatic resection (96 patients) or TACE (134 patients). The baseline characteristics, tumor characteristics, clinicopathological parameters, and overall survival rates were compared between the 2 groups. The baseline and tumor characteristics were comparable between the hepatic resection and TACE groups. The overall complication rate was 35.4% in the hepatic resection group, which was significantly lower than that in the TACE group (73.0%, P<0.001). However, the serious complication rate (grade 3) in the hepatic resection group was 13.5%, which was significantly higher than that in the TACE group (P = 0.003). The cumulative overall survival rates at 1, 3, and 5 years in the hepatic resection group were 86.5%, 60.4%, and 33.3%, respectively. These rates were much higher than those in the TACE group (1-year: 77.6%; 3-year: 47.8%; and 5-year: 20.9%; P = 0.021). The long-term survival was notably better in the patients with types I and II PVTT than in the patients with types III and IV PVTT (P<0.05). The univariate and multivariate analyses indicated that types III and IV PVTT and TACE may have contributed to the poor overall survival following surgery. In HCC patients with PVTT and compensated liver function, hepatic resection is a safe and effective surgical protocol, particularly for patients with type I or II PVTT.
机译:肝切除在肝细胞癌(HCC)中具有伴随门静脉肿瘤血栓(PVTT)的作用仍然存在争议。该研究旨在评估肝切除术的手术结果与HCC患者的常规化疗栓塞(TACE)相比。使用230例HCC患者的患者进行了回顾性研究,该患者门静脉侵袭肝切除(96例)或TACE(134名患者)。在2组之间比较了基线特征,肿瘤特征,临床病理学参数和整体存活率。基线和肿瘤特性在肝切除术和TACE组之间具有可比性。肝切除术组的整体并发症率为35.4%,其显着低于TACE组(73.0%,P <0.001)。然而,肝切除术组中的严重并发症率(3级)为13.5%,其显着高于TACE组(P = 0.003)。肝切除组1,3和5年的累积总存活率分别为86.5%,60.4%和33.3%。这些利率远高于TACE组(1年:77.6%; 3年:47.8%;和5年:20.9%; P = 0.021)。 I型和II型PVTT患者的长期存活率比III型和IV型PVTT患者(P <0.05)。单变量和多变量分析表明III型和IV PVTT和TACE可能导致手术后的差的整体存活。在具有PVTT和补偿肝功能的HCC患者中,肝切除是一种安全有效的手术方案,特别是对于I型或II PVTT的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号